People · Operator
Named in public records as an officer, director or promoter · active 2012–2024 · Pharmaceuticals, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Antios Therapeutics Inc. | — | Pharmaceuticals | Series C | $126.4M | $1.7B | 2021 |
| Reunion Neuroscience, Inc. | — | Pharmaceuticals | Series D+ | $119.8M | $1.5B | 2024 |
| Unigene Laboratories Inc | — | Biotechnology | Series B | $37.8M | $29.8M | 2012 |
| Receptor Holdings, Inc. | — | Pharmaceuticals | Series B | $36.2M | $141.0M | 2021 |
| Engage Therapeutics, Inc. | — | Pharmaceuticals | Series B | $30.6M | $238.0M | 2017 |
Gregory Mayes at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Gregory Mayes on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Mark Theeuwes | 3 | 3 |
| Warren Lammert | 2 | 3 |
| Heath Lukatch | 1 | 10 |
| Briggs Morrison | 1 | 8 |
| Ansbert Gadicke | 1 | 7 |
| Alon Lazarus | 1 | 7 |
| Craig Gordon | 1 | 6 |
| Robert Alexander | 1 | 6 |
| Michael Ehlers | 1 | 6 |
| Gerry Brunk | 1 | 5 |
| Stephen Collins | 1 | 5 |
| Edward Smith | 1 | 5 |
| NICOLE VITULLO | 1 | 4 |
| Richard Levy | 1 | 4 |
| Richard S. Levy | 1 | 4 |
| Arthur Rubinfeld | 1 | 4 |
| Benjamin Rovinski | 1 | 3 |
| Nathan Bryson | 1 | 3 |
| Iyona Rajkomar | 1 | 3 |
| Orrin Devinsky | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.